CRISPR

CRISPR1-nr2f1a

ID

ZDB-CRISPR-180606-1

Name

CRISPR1-nr2f1a

Previous Names

None

Target

nr2f1a (1)

Sequence

5' - GGCCAGTATGCGCTAACGAATGG - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
ci1009	nr2f1a

Expression

Gene expression in Wild Types + CRISPR1-nr2f1a

No data available

Phenotype

Phenotype resulting from CRISPR1-nr2f1a

No data available

Phenotype of all Fish created by or utilizing CRISPR1-nr2f1a

Phenotype	Fish	Conditions	Figures
cardiac ventricle cardiac muscle cell Ab3-vmhc labeling increased distribution, abnormal	nr2f1a^{ci1009/ci1009}	standard conditions	Fig. 1 from Martin et al., 2026
blood circulation disrupted, abnormal	nr2f1a^{ci1009/ci1009}	standard conditions	Fig. S2 from Duong et al., 2017
atrium cardiac muscle cell ab-s46 labeling decreased distribution, abnormal	nr2f1a^{ci1009/ci1009}	standard conditions	Fig. 1 from Martin et al., 2026
pericardium edematous, abnormal	nr2f1a^{ci1009/ci1009}	standard conditions	Fig. S2 from Duong et al., 2017
atrial myocardium cardiac muscle cell tbx18 expression mislocalised, abnormal	nr2f1a^{ci1009/ci1009}; sd7Tg/sd7Tg	standard conditions	Fig. 8 from Martin et al., 2026
cardiac conduction system cardiac cell fate commitment spatial distribution of a process, abnormal	nr2f1a^{ci1009/ci1009}; sd7Tg/sd7Tg	standard conditions	Fig. 8 from Martin et al., 2026
atrial myocardium cardiac muscle cell mybpc3 expression mislocalised, abnormal	nr2f1a^{ci1009/ci1009}; sd7Tg/sd7Tg	standard conditions	Fig. 8 from Martin et al., 2026
atrial myocardium cardiac muscle cell myh7l expression mislocalised, abnormal	nr2f1a^{ci1009/ci1009}; sd7Tg/sd7Tg	standard conditions	Fig. 8 from Martin et al., 2026
cardiac ventricle cardiac conduction system EGFP expression increased distribution, abnormal	nr2f1a^{ci1009/ci1009}; sqet33mi59BEt/sqet33mi59BEt	standard conditions	Fig. 2 from Martin et al., 2026
cardiac ventricle cardiac muscle cell Ab3-vmhc labeling increased distribution, abnormal	nr2f1a^{ci1009/ci1009}; sqet33mi59BEt/sqet33mi59BEt	standard conditions	Fig. 2 from Martin et al., 2026
atrial myocardium EGFP expression increased distribution, abnormal	nr2f1a^{ci1009/ci1009}; sqet33mi59BEt/sqet33mi59BEt	standard conditions	Fig. 4 from Martin et al., 2026
atrial myocardium EGFP expression spatial pattern, abnormal	nr2f1a^{ci1009/ci1009}; sqet33mi59BEt/sqet33mi59BEt	standard conditions	Fig. 4 from Martin et al., 2026
cardiac ventricle cardiac muscle cell ab-s46 labeling decreased distribution, abnormal	nr2f1a^{ci1009/ci1009}; sqet33mi59BEt/sqet33mi59BEt	standard conditions	Fig. 2 from Martin et al., 2026
cardiac ventricle cardiac muscle cell Ab3-vmhc labeling increased distribution, abnormal	isl1a^{ci1032/ci1032}; nr2f1a^{ci1009/ci1009}	standard conditions	Fig. 1 from Martin et al., 2026
atrium cardiac muscle cell ab-s46 labeling decreased distribution, abnormal	isl1a^{ci1032/ci1032}; nr2f1a^{ci1009/ci1009}	standard conditions	Fig. 1 from Martin et al., 2026
cardiac ventricle cardiac conduction system GCaMP expression spatial pattern, abnormal	isl1a^{ci1032/ci1032}; nr2f1a^{ci1009/ci1009}; ci1031Tg/ci1031Tg	standard conditions	Fig. 3 from Martin et al., 2026
cardiac conduction system heart contraction irregular rhythm, abnormal	isl1a^{ci1032/ci1032}; nr2f1a^{ci1009/ci1009}; ci1031Tg/ci1031Tg	standard conditions	Fig. 3 from Martin et al., 2026
cardiac ventricle cardiac conduction system GCaMP expression spatial pattern, ameliorated	isl1a^{ci1032/ci1032}; nr2f1a^{ci1009/ci1009}; ci1031Tg/ci1031Tg	standard conditions	Fig. 3 from Martin et al., 2026
cardiac conduction system heart contraction rhythm quality, abnormal	isl1a^{ci1032/ci1032}; nr2f1a^{ci1009/ci1009}; ci1031Tg/ci1031Tg	standard conditions	Fig. 3 from Martin et al., 2026
atrial myocardium DsRed2 expression spatial pattern, abnormal	isl1a^{ci1032/ci1032}; nr2f1a^{ci1009/ci1009}; f2Tg/f2Tg; pd41Tg/pd41Tg	standard conditions	Fig. 6 from Martin et al., 2026
atrial myocardium ab-s46 labeling spatial pattern, abnormal	isl1a^{ci1032/ci1032}; nr2f1a^{ci1009/ci1009}; f2Tg/f2Tg; pd41Tg/pd41Tg	standard conditions	Fig. 6 from Martin et al., 2026
epicardium EGFP expression spatial pattern, abnormal	isl1a^{ci1032/ci1032}; nr2f1a^{ci1009/ci1009}; f2Tg/f2Tg; pd41Tg/pd41Tg	standard conditions	Fig. 6 from Martin et al., 2026
cardiac conduction system cardiac cell fate specification spatial distribution of a process, abnormal	isl1a^{ci1032/ci1032}; nr2f1a^{ci1009/ci1009}; f2Tg/f2Tg; pd41Tg/pd41Tg	standard conditions	Fig. 6 from Martin et al., 2026
atrial myocardium DsRed2 expression spatial pattern, abnormal	isl1a^{ci1032/ci1032}; nr2f1a^{ci1009/ci1009}; f2Tg/f2Tg; sqet33mi59BEt/sqet33mi59BEt	standard conditions	Fig. 5 from Martin et al., 2026
atrial myocardium EGFP expression decreased distribution, abnormal	isl1a^{ci1032/ci1032}; nr2f1a^{ci1009/ci1009}; f2Tg/f2Tg; sqet33mi59BEt/sqet33mi59BEt	standard conditions	Fig. 5 from Martin et al., 2026
atrial myocardium ab-s46 labeling spatial pattern, abnormal	isl1a^{ci1032/ci1032}; nr2f1a^{ci1009/ci1009}; f2Tg/f2Tg; sqet33mi59BEt/sqet33mi59BEt	standard conditions	Fig. 5 from Martin et al., 2026
atrial myocardium EGFP expression spatial pattern, abnormal	isl1a^{ci1032/ci1032}; nr2f1a^{ci1009/ci1009}; f2Tg/f2Tg; sqet33mi59BEt/sqet33mi59BEt	standard conditions	Fig. 5 from Martin et al., 2026
atrial myocardium DsRed2 expression decreased distribution, abnormal	isl1a^{ci1032/ci1032}; nr2f1a^{ci1009/ci1009}; f2Tg/f2Tg; sqet33mi59BEt/sqet33mi59BEt	standard conditions	Fig. 5 from Martin et al., 2026
cardiac conduction system cardiac cell fate specification spatial distribution of a process, abnormal	isl1a^{ci1032/ci1032}; nr2f1a^{ci1009/ci1009}; f2Tg/f2Tg; sqet33mi59BEt/sqet33mi59BEt	standard conditions	Fig. 5 from Martin et al., 2026
atrial myocardium ab-s46 labeling spatial pattern, abnormal	isl1a^{ci1032/ci1032}; nr2f1a^{ci1009/ci1009}; fb2Tg/fb2Tg; sd20Tg/sd20Tg	chemical treatment by environment: tamoxifen	Fig. 7 from Martin et al., 2026
atrial myocardium cardiac muscle cell ab-s46 labeling absent, abnormal	isl1a^{ci1032/ci1032}; nr2f1a^{ci1009/ci1009}; fb2Tg/fb2Tg; sd20Tg/sd20Tg	chemical treatment by environment: tamoxifen	Fig. 7 from Martin et al., 2026
cardiac conduction system cardiac cell fate commitment spatial distribution of a process, abnormal	isl1a^{ci1032/ci1032}; nr2f1a^{ci1009/ci1009}; fb2Tg/fb2Tg; sd20Tg/sd20Tg	chemical treatment by environment: tamoxifen	Fig. 7 from Martin et al., 2026
atrial myocardium ZsYellow expression spatial pattern, abnormal	isl1a^{ci1032/ci1032}; nr2f1a^{ci1009/ci1009}; fb2Tg/fb2Tg; sd20Tg/sd20Tg	chemical treatment by environment: tamoxifen	Fig. 7 from Martin et al., 2026
atrial myocardium cardiac muscle cell tbx18 expression mislocalised, abnormal	isl1a^{ci1032/ci1032}; nr2f1a^{ci1009/ci1009}; sd7Tg/sd7Tg	standard conditions	Fig. 8 , Fig. 9 from Martin et al., 2026
cardiac ventricle myh7l expression mislocalised, abnormal	isl1a^{ci1032/ci1032}; nr2f1a^{ci1009/ci1009}; sd7Tg/sd7Tg	standard conditions	Fig. 9 from Martin et al., 2026
cardiac conduction system cardiac cell fate commitment spatial distribution of a process, abnormal	isl1a^{ci1032/ci1032}; nr2f1a^{ci1009/ci1009}; sd7Tg/sd7Tg	standard conditions	Fig. 8 from Martin et al., 2026
atrial myocardium cardiac muscle cell mybpc3 expression mislocalised, abnormal	isl1a^{ci1032/ci1032}; nr2f1a^{ci1009/ci1009}; sd7Tg/sd7Tg	standard conditions	Fig. 8 from Martin et al., 2026
atrial myocardium cardiac muscle cell myh7l expression mislocalised, abnormal	isl1a^{ci1032/ci1032}; nr2f1a^{ci1009/ci1009}; sd7Tg/sd7Tg	standard conditions	Fig. 8 from Martin et al., 2026
cardiac ventricle cardiac muscle cell myh7l expression increased distribution, abnormal	isl1a^{ci1032/ci1032}; nr2f1a^{ci1009/ci1009}; sd7Tg/sd7Tg	standard conditions	Fig. 9 from Martin et al., 2026
cardiac ventricle cardiac muscle cell Ab3-vmhc labeling increased distribution, abnormal	isl1a^{ci1032/ci1032}; nr2f1a^{ci1009/ci1009}; sqet33mi59BEt/sqet33mi59BEt	standard conditions	Fig. 2 from Martin et al., 2026
atrium cardiac muscle cell ab-s46 labeling decreased distribution, abnormal	isl1a^{ci1032/ci1032}; nr2f1a^{ci1009/ci1009}; sqet33mi59BEt/sqet33mi59BEt	standard conditions	Fig. 2 from Martin et al., 2026
cardiac ventricle cardiac conduction system EGFP expression decreased distribution, abnormal	isl1a^{ci1032/ci1032}; nr2f1a^{ci1009/ci1009}; sqet33mi59BEt/sqet33mi59BEt	standard conditions	Fig. 2 from Martin et al., 2026
atrial myocardium ab-s46 labeling spatial pattern, abnormal	isl1a^{ci1032/ci1032}; nr2f1a^{ci1009/ci1009}; sqet33mi59BEt/sqet33mi59BEt	standard conditions	Fig. 4 from Martin et al., 2026
atrial myocardium Ab3-vmhc labeling increased distribution, abnormal	isl1a^{ci1032/ci1032}; nr2f1a^{ci1009/ci1009}; sqet33mi59BEt/sqet33mi59BEt	standard conditions	Fig. 4 from Martin et al., 2026
atrial myocardium EGFP expression increased distribution, abnormal	isl1a^{ci1032/ci1032}; nr2f1a^{ci1009/ci1009}; sqet33mi59BEt/sqet33mi59BEt	standard conditions	Fig. 4 from Martin et al., 2026
atrial myocardium EGFP expression spatial pattern, abnormal	isl1a^{ci1032/ci1032}; nr2f1a^{ci1009/ci1009}; sqet33mi59BEt/sqet33mi59BEt	standard conditions	Fig. 4 from Martin et al., 2026
cardiac conduction system cardiac cell fate commitment spatial distribution of a process, abnormal	isl1a^{ci1032/ci1032}; nr2f1a^{ci1009/ci1009}; pd41Tg/pd41Tg + CRISPR2-tbx18 + CRISPR3-tbx18	standard conditions	Fig. 11 from Martin et al., 2026
atrial myocardium cardiac muscle cell EGFP expression mislocalised, abnormal	isl1a^{ci1032/ci1032}; nr2f1a^{ci1009/ci1009}; pd41Tg/pd41Tg + CRISPR2-tbx18 + CRISPR3-tbx18	standard conditions	Fig. 11 from Martin et al., 2026
epicardium EGFP expression spatial pattern, abnormal	isl1a^{ci1032/ci1032}; nr2f1a^{ci1009/ci1009}; pd41Tg/pd41Tg + CRISPR2-tbx18 + CRISPR3-tbx18	standard conditions	Fig. 11 from Martin et al., 2026
atrial myocardium EGFP expression spatial pattern, abnormal	isl1a^{ci1032/ci1032}; nr2f1a^{ci1009/ci1009}; pd41Tg/pd41Tg + CRISPR6-tcf21 + CRISPR7-tcf21	standard conditions	Fig. 10 from Martin et al., 2026
cardiac conduction system cardiac cell fate commitment spatial distribution of a process, abnormal	isl1a^{ci1032/ci1032}; nr2f1a^{ci1009/ci1009}; pd41Tg/pd41Tg + CRISPR6-tcf21 + CRISPR7-tcf21	standard conditions	Fig. 10 from Martin et al., 2026

Citations